Gene-based therapy of malignant melanoma
- 1 October 2002
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 29 (5) , 503-512
- https://doi.org/10.1053/sonc.2002.35245
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCRGene Therapy, 2000
- Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cellsCancer Gene Therapy, 2000
- Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumorsCancer Gene Therapy, 2000
- Immunological Gene Therapy withex VivoGene-Modified Tumor Cells: A Critique and a ReappraisalHuman Gene Therapy, 2000
- Vaccination of Melanoma Patients with an Allogeneic, Genetically Modified Interleukin 2-Producing Melanoma Cell LineHuman Gene Therapy, 2000
- Immunotherapy of Metastatic Malignant Melanoma by a Vaccine Consisting of Autologous Interleukin 2-Transfected Cancer Cells: Outcome of a Phase I StudyHuman Gene Therapy, 1999
- Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I studyGene Therapy, 1998
- Limited Antitumor T Cell Response in Melanoma Patients Vaccinated with Interleukin-2 Gene-Transduced Allogeneic Melanoma CellsHuman Gene Therapy, 1996
- Current therapy for cutaneous melanomaJournal of the American Academy of Dermatology, 1995
- Murine interleukin-4 displays potent anti-tumor activity in vivoCell, 1989